ghp lobal health & pharma Q3 2026 www.ghp-news.com Gut Feeling PrecisionBiotics® helps people take control of their own health by unlocking the power of the human microbiome. In addition to developing high-quality food supplements containing unique bacterial strains, the firm is dedicated to providing a wealth of information and resources to help people understand, take control, and harness the natural power of their gut microbiome for better health and wellbeing.
Welcome to the latest issue of Global Health & Pharma magazine, providing you with all of the latest news and features across the healthcare and pharmaceutical landscape. Q3 2026 Our Q3 2026 issue is here to celebrate the innovative updates in this integral sphere, as well as the award-worthy excellence of the companies and individuals who are leading positive change. Throughout these pages, we delve deeper into what makes our awardees so special. From physical therapy to mental wellbeing services, our winners’ offerings cover everything needed to enrich our quality of life both now and in the future. PrecisionBiotics, our cover feature and esteemed recipient of Best Gut Health Supplement Brand 2026, is another shining example of what it means to be dedicated to delivering lifechanging products that support a healthier, happier lifestyle. We hope you enjoy reading this quarter’s issue and we can’t wait to welcome you back again in a few months for our final edition of 2026. Sofi Parry, Senior Editor Website: ghpnews.digital AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.
Contents 6. News - NUS Scientists Harness Magnetic Pulses to Reprogram Immune Cells to Fight Breast Cancer - Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 9. Gut Feeling 10. CLINIGMA®: Leaders in Patient-Centric Clinical Innovation 2026 11. Healthcare Streamlined with ScienceSoft 12. Astrobiome Space: Pioneering the Next Era of Microbiome Therapeutics 13. Leading the Regenerative Revolution in Aesthetics and Skincare 14. A Clean Sweep 16. Medical Logistics: “Your Customer, Our Care” 17. The Top Choice for Physical Therapy in Indiana 18. Doctor-Led, Patient-Centred Medical Aesthetics 19. Zenagen: Where Haircare Begins with the Scalp 20. Effortless, Science- Backed, Scalp-First 21. Nurse-Led Medical Aesthetics 22. The Ultimate Healthcare One-Stop Shop 23. Mastering the Subconscious 24. A Different Kind of Healthcare Company 25. Doctor-Led Aesthetics 26. Preclinical Research Innovation 27. Where Beauty Meets Innovation 28. Supporting Skin Health at a Cellular Level 30. Soothe Your Skin with Nature 31. Certified-Organic, Skin-Loving Self Tan from Australia 32. Why People in 140 Countries Choose International Plus for Medical Tourism 34. Best Foot Forward
35. Interfilling: Bringing Beauty Brands from Concept to Market 36. Redefining Medication Safety 38. Medical Expertise Meets Ethical Aesthetics 39. More than Skin Deep 40. Totally Derma®: Formulating a Future of Science-Backed Skin Health 41. Beyond Injury: The Future of Movement Health 42. Europe Surgery: World-Class Cosmetic Surgery, Made Accessible 43. Dr. Claire Taylor: An Advocate for the Unheard 44. Happy Carers and Better Care with Scotland’s Trust-Care Staffing 45. Medical Aesthetics for Every Skin Type 46. ONE Chiropractic Studio: One Shared Mission 48. Hyper-Personalised Facial Treatments that Bring the WOW Factor 49. Redefining Modern Aesthetics 50. Patient-Centred, Safe, and Effective Remote GP Support 51. Nurse-Led Aesthetics Accentuating Natural Beauty 52. Healthy Ageing Starts with Stronger Cells 53. Certified Vegan Supplementation That Works 54. Island Eyecare: Best Ocular Health Clinic & Treatment Center 2026 - British Columbia 55. Science-Backed, Patient-Centred Aesthetics Excellence 56. Oral Care with a Perfect Blend of Science and Nature Contents
ghp lobal health & pharma Content Delivered To You Embark on an exciting journey with us! Subscribe now to access exclusive content and become part of our thriving community. Subscribe Today
NEWS Researchers from the National University of Singapore (NUS) have demonstrated an innovative approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs). The NUS team successfully reprogrammed tumour-associated macrophages (TAMs), a corrupted class of immune cells that typically promote cancer growth, into an active anti-tumour state that attacks and destroys cancer cells. The study, led by Associate Professor Alfredo Franco-Obregón from the Department of Surgery at the NUS Yong Loo Lin School of Medicine and the NUS Institute for Health Innovation & Technology, was published in the journal Smart Medicine on 4 June 2026. This discovery builds on their previous work, where they showed that NUS Scientists Harness Magnetic Pulses to Reprogram Immune Cells to Fight Breast Cancer brief PEMF exposure enhances uptake of doxorubicin (DOX), a chemotherapy drug, by breast cancer cells. PEMF therapy applies intermittent, lowintensity magnetic pulses to targeted regions of the body over a short period of time. Assoc Prof Franco-Obregón has previously explored the effect of PEMFs on muscle development and oncology. In their latest study, the NUS team demonstrated that even without chemotherapy, PEMFs completely eradicated tumours in 75 per cent of tested preclinical models after just four 30-minute sessions. “Our study represents a major advancement in breast cancer treatment by demonstrating the potential of PEMFs as a stand-alone, drug-free therapy, offering a possible future where patients could avoid chemotherapy and its debilitating side effects,” said Assoc Prof Franco-Obregón. Breast cancer cases are projected to rise by a third, from 2.3 million in 2023 to more than 3.5 million by 2050, while annual deaths may nearly double from 764,000 to nearly 1.4 million. Cancer treatment faces challenges such as tumour heterogeneity, drug resistance, and treatment-related toxicities. Approaches targeting TAMs also faced difficulties such as off-target effects. The growing burden underscores the urgent need for innovative therapies to improve patient outcomes and save lives. From cancer’s friends to foes Breast cancer occurs when cells in the breast mutate and grow uncontrollably, forming a solid tumour. These cancer cells recruit and hijack nearby immune cells, corrupting them to protect the tumour, accelerate tumour growth, and encourage the spread of cancer (metastasis). An innovative approach for breast cancer treatment uses localised and non-invasive pulsed electromagnetic fields to reprogram immune cells, turning them from tumour helpers to cancer killers
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Potentially accelerating the path to market for this innovative antibacterial treatment AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation Armata Pharmaceuticals, Inc., a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, announced that the U.S. Food and Drug Administration (the “FDA”) has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillinresistant S. aureus (“MRSA”). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies. “The decision by the FDA to grant Breakthrough Therapy designation to APSA02, in addition to Qualified Infectious Disease Product (“QIDP”) and Fast Track designations, recognizes the urgent need for new treatment options for patients with complicated S. aureus bacteremia (“SAB”), including MRSA, where many outcomes remain poor despite current standard-of-care,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “Based on the Phase 2 clinical trial data, we believe AP-SA02 has the potential to represent an important advancement in the treatment of complicated SAB, a serious bloodstream infection that continues to be associated with significant relapse rate, morbidity and mortality. If ultimately confirmed in Phase 3 and approved, AP-SA02 has the potential to become the first antibacterial therapy approved based on superiority to current standard-ofcare treatment in this patient population. We are grateful for the FDA’s enhanced engagement and are committed to working closely with the Agency to efficiently advance the development and review of AP-SA02, with the goal of bringing this potential new treatment option to patients as quickly as possible.” Critically, the Breakthrough Therapy designation is supported by data from the successful Phase 1b/2a diSArm study in adults with complicated SAB. Armata’s proprietary purification process yielded the production of a high-purity, hightiter AP-SA02 drug product formulation enabling repetitive dose intravenous administration every six hours for five days. This dosing regimen was well tolerated with no serious adverse events attributed to AP-SA02, and, when added to best available antibiotic therapy (“BAT”) demonstrated higher and earlier clinical cure rates than placebo plus BAT. At the end-of-study assessment, 28 days after completion of BAT, 100% of patients treated with AP-SA02 maintained clinical response without relapse, compared with 75% of patients receiving placebo. Patients treated with AP-SA02 also demonstrated favorable trends across multiple measures of disease resolution, including more rapid normalization of C-reactive protein (CRP) and Interleukin-10 (IL-10), biomarkers associated with mortality risk and complications in SAB. Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Prominent among these recruited immune cells are TAMs, which are abundant in nearly all solid tumours. There are two primary types of macrophages, M1 and M2. M1 macrophages are pro-inflammatory – the “soldiers” that eliminate threats like bacteria and viruses. M2 macrophages are anti-inflammatory – the “medics” that orchestrate wound healing and tissue repair once threats are cleared. Cancer cells corrupt most TAMs into adopting the M2 “medic” state, suppressing immune attacks against the tumour while facilitating tumour growth and metastasis. The key to this macrophage reprogramming lies in a protein called TRPC1 (Transient Receptor Potential Canonical 1), which regulates the M1 state. Crucially, TRPC1 also allows cells to sense and respond to magnetic fields. In their experiments, the NUS team confirmed that a brief 10-minute exposure to PEMFs activated TRPC1 channels on M2-like TAMs, setting off a signalling cascade that converted them to the M1 state – essentially turning TAMs from helpful “medics” to aggressive cancerkilling “soldiers”. These activated TAMs then selectively target cancer cells while sparing healthy tissue. Furthermore, the same magnetic signature disrupts cancer’s ability to hijack TAMs, altering the TAM-cancer communication loop in both directions. “We have identified a molecular “switch”, the specific cell signalling pathway that allows us to reprogram TAMs. Once reprogrammed, these immune cells actively hunt and devour cancer cells, obliterating the tumour,” said Assoc Prof Franco-Obregón. “With the non-invasive and targeted nature of PEMF therapy, we hope to provide patients an effective and safe alternative treatment, with fewer undesirable side effects.” Pulses of hope for cancer patients Assoc Prof Franco-Obregón shared that the same PEMF device used in this study has just successfully completed Phase 1 clinical trials, demonstrating its safety in humans. The team is now seeking partners to conduct Phase 2 efficacy trials to evaluate how well the PEMF treatment works in patients and to further advance its development towards clinical use. “Since we previously showed that PEMFs selectively increased the uptake of DOX in breast cancer cells, we will be evaluating if our PEMF immunotherapy can work synergistically with chemotherapy for better results,” added Assoc Prof Franco-Obregón. “As the immune cells we reprogram are commonly found in most solid tumours, we are optimistic that our PEMF therapy could potentially be a complementary treatment for other cancers beyond breast cancer.” Read more: https://news.nus.edu.sg/ magnetic-pulses-reprogram-immune-cellsto-fight-breast-cancer
Introducing the GHP Global Excellence Awards Launched in 2020, the Global Excellence Awards provide us at Global Health & Pharma Magazine with an opportunity to celebrate and highlight the innovative companies, teams and individuals who are excelling across the vast landscape encompassing healthcare, life science and pharmaceutical sectors. Our recipients are hand selected by our very own inhouse research team over several months. We search diligently to find those setting the highest standards, making pioneering breakthroughs and creating the most cutting-edge medical solutions; from Health & Pharma Tech innovators to care service providers and everything in between, we seek to showcase outstanding medical, health and pharmaceutical business leaders and companies from across the globe.
9 GHP Q3 2026 Gut Feeling ith a long-standing reputation for developing products supported by rigorous scientific research, PrecisionBiotics was founded 25 years ago by scientists who believed the human microbiome contains the answers to many modern health problems. Together, they researched thousands of bacterial cultures along with experts from one of the world’s leading centres of microbiome research, the APC Microbiome Institute. Today, PrecisionBiotics is part of Novonesis OneHealth and working with human health centres of excellence across the world, with access to the world’s largest collection of bacterial strains and thousands of enzymes that help further its dedication to find sustainable solutions for future generations. PrecisionBiotics differentiates itself within the industry thanks to its precise and proven science, namely the discovery of Alflorex which is the only probiotic in the UK to contain the unique Bifidobacterium longum 35624TM bacterial strain. Alflorex has been studied in 13 randomised clinical trials and real-world studies for IBS, with a well-documented safety profile from research trials and post-marketing surveillance and has demonstrated significant improvements in symptom severity compared to placebo. This strain is also recognised by international guidelines including the European Society of Primary Care Gastroenterology for its support in helping to relieve overall symptom burden, and for being effective in managing IBS symptoms by the WGO Global Guidelines. Another product discovered and developed by PrecisionBiotics® is Alflorex Dual Action, which contains two unique strains: B.longum 35624TM and B.longum 1714TM, proven to reach the gut in peak condition. The product also contains calcium and B vitamins to support gut and mental health and is leading the way for education around the gut-brain connection. Recent developments in the industry have seen updated guidelines from The Rome Foundation (Rome V) relating to Irritable Bowel Syndrome (IBS) diagnosis and care. Most notably, the criteria re-include “discomfort” alongside pain and lower the symptom threshold to three days per month, which replaces the stricter Rome IV requirement of pain at least once a week. This latest development supports PrecisionBiotics® Dual Action product, which addresses both the gut and the mind. For the past 30 years, gastrointestinal disorders have been recognised as common and disruptive – causing pain, nausea, vomiting, diarrhoea, and constipation. When these symptoms begin to interfere with daily life, patients seek medical care. However, when testing yields no organic causes for their persistent symptoms, patients are frequently told that “nothing is wrong”. PrecisionBiotics® helps people take control of their own health by unlocking the power of the human microbiome. In addition to developing high-quality food supplements containing unique bacterial strains, the firm is dedicated to providing a wealth of information and resources to help people understand, take control, and harness the natural power of their gut microbiome for better health and wellbeing. The Rome Foundation has worked to change this narrative. By bringing together leading researchers and clinicians from around the world, the Foundation has advanced the understanding of these conditions and advanced the understanding of the complex pathophysiology of these conditions and an improved understanding of the complex interactions between the gut and brain. The Foundation created diagnostic symptom-based criteria, which has recently transformed the concept of functional gastrointestinal disorders (FGID) into Disorders of Gut-Brain Interaction (DGBI), a more accurate framework that is increasingly accepted and utilised globally. This effort legitimised these prevalent conditions, promoted the development of novel therapeutics, and improved outcomes and quality of life for patients. Rome V marks a new era in the classification and care of DGBI. This updated framework reflects the latest science and emphasises a more compassionate, patient-centred, and biologically grounded approach to diagnosis and treatment. Rome V empowers clinicians to make positive, evidence-based diagnoses, moving beyond exclusion and toward personalised, compassionate care. Building on validated instruments and new translational data, Rome V integrates more rigorous scientific methods to define disease mechanisms and identify clinically relevant subgroups. It broadens the evidence base by incorporating studies in previously under-represented populations and by refining pediatric DGBI categories to align with emerging neurodevelopmental and mechanistic insights. Recently recognised for its diligence to the continued research and development of bacterial cultures, PrecisionBiotics® was named Best Gut Health Supplement Brand 2026 in the Global Excellence Awards 2026. Now, the organisation is looking at the emerging category of psychobiotics, with a bigger focus on its B. Longum 1714TM strain, which in randomised, double blind, placebo-controlled studies which has been shown to influence stress responses and modulate neural responses during social stress, and influence sleep quality during examination stress in healthy adults. Contact: Alison Hunter Pease Company: PrecisionBiotics® Alflorex Web Address: www.precisionbiotics.co.uk W
10 GHP Q3 2026 CLINIGMA® is the only clinical research organisation with a system built specifically to capture trial patients’ own words during clinical trials, in full ICH-GCP compliance. Working with pharmaceutical companies worldwide, it currently interviews trial patients in 35+ countries at every stage of drug development, giving patients a structured voice in the process. To understand the work behind this recognition, we spoke with Founder and CEO Jens Harald Kongsø. In-trial patient interviews capture how patients actually experience a treatment during the trial itself, in their own words. Done well, that evidence can support regulatory submissions, labelling claims, and commercial decision making. It is a way of bringing the patient’s perspective into decisions usually made on numbers alone. Jens Harald explained: “In-trial interviews were wisely encouraged by the regulatory bodies, led by the FDA’s Patient-Focused Drug Development initiatives, in particular in rare diseases. We now see pharmaceutical companies not only using trial patients’ feedback to help inform the regulatory bodies, but also using that firsthand feedback to optimise drug development within their own organisations. It is very rewarding to help pharma companies unlock the value of their new drugs and to help inform the regulatory bodies. It is just as fulfilling when we get a ‘thank you for listening to me’ from a trial patient.” The innovation behind this recognition is the CLINIGMA Portal. Under ICH-GCP, what a patient says in an in-trial interview is source data, so it must be managed to the same standard as the rest of the trial and stand up to inspection. That calls for a system built for the purpose: access is controlled, every action carries a full audit trail, and the data cannot be altered after the fact. It also protects patients: when an interviewer records a potential serious event affecting a patient’s safety, the system requires and timestamps the escalation to their investigator, as auditable proof the patient was protected under the protocol. Keeping interviews on time and tied to the trial matters, but the more important thing is that everything the Portal captures can be trusted as evidence when the authorities look. This is where much of the industry still falls short. Offering in-trial interviews is not the same as conducting them so they survive a GCP inspection. Contact details sit in spreadsheets emailed around, interviews are captured on consumer tools never validated for clinical use, and source recordings are deleted once a transcript exists, leaving no way to prove it was not altered. With AI making records easy to change, that gap only grows unless the data is retained in full as GCP source data. Such shortcuts risk data being rejected, reworked, or flagged during inspection. The Portal was built to close them and remains the only system of its kind. Rigor depends on people as much as systems. “Every interview methodology we use is designed to hold up to regulatory scrutiny,” Jens told us, “because rigorous data is what ultimately ensures the patient voice has impact.” In-trial interviews are the core of CLINIGMA’s business rather than one service among many, delivered by a scientific team with deep experience in qualitative patient research to ICH-GCP standards. “Behind every study is our global team of 300+ master’s and PhD-level researchers, covering 100+ natively spoken languages and trained in ICH-GCP and projectspecific requirements to ensure patient safety, ethics, and high-quality data collection.” The innovation continues with the CLINIGMA Explorer, giving pharmaceutical teams direct access to the interview transcripts rather than a final report alone. As patient-focused drug development guidance matures in the US and EU, these tools keep clients ahead of requirements rather than reacting. In an industry where data validation and AI dominate the conversation, Jens is clear on the latter: “Our position is that AI is a tool that supports our researchers, not a replacement for the human expertise that regulatory-grade qualitative research requires. This is in line with the regulatory bodies’ recommendations. We continue to explore how AI can support strong patient-centred research while we maintain rigorous human oversight, full ICH-GCP compliance, and data integrity.” Education is a priority too. CLINIGMA shares knowledge through conferences, webinars, a LinkedIn video series, a newsletter, and a free template library for clinical research professionals. Plenty of providers can conduct an interview. The harder task is doing it so the data holds up to ICH-GCP and local data privacy law, and that is what CLINIGMA specialises in, currently working in 35+ countries for most of the world’s largest pharmaceutical companies. For getting that right, and for the system that makes it possible, we are proud to recognise CLINIGMA® as Leaders in Patient-Centric Clinical Innovation 2026. Contact: Jens Harald Kongsø Company: CLINIGMA® Web Address: www.clinigma.com Leaders in Patient-Centric Clinical Innovation 2026 AIM-Mar26373
11 GHP Q3 2026 o begin, could you tell us about ScienceSoft’s mission and he principles that guide your work? Our mission is to reduce care costs and improve patient outcomes through technology. To achieve this, we look at the process as a whole and ask which changes could bring the greatest clinical or financial value. Then we work out how to make these changes possible. The same problem can often be addressed in several ways, and the most suitable option depends on the organization’s current processes, technology environment, budget, internal capabilities, and long-term plans. We help clients compare the options and choose an approach that is realistic, cost-effective, and capable of producing a meaningful result in their environment. How does ScienceSoft organize its work to manage the complexity of healthcare IT projects? We organize software delivery around three dedicated units: The Project Management Office keeps delivery predictable and transparent. Our certified project managers use shared practices for planning, estimation, change management, reporting, and stakeholder communication. They raise risks early, keep decisions and responsibilities clear, and involve other experienced PMs when complex delivery situations call for a second opinion. The Architecture & Solutions Center of Excellence, led by nine principal architects with 15–25+ years of experience, designs secure and cost-efficient architectures aligned with applicable compliance requirements. Our architects plan for interoperability with internal and partner systems (including legacy solutions) and apply proven patterns for scalability, cloud readiness, performance, and long-term maintainability. The Technology & Competency Center of Excellence helps match each project with people who have relevant domain-specific and technical experience. It could be knowledge of specific data exchange standards and formats (e.g., ASTM and CLSI for laboratories; DICOM for imaging; X12 for billing) or clinical coding and terminology systems such as ICD-10, CPT, SNOMED CT, LOINC, and RxNorm. In December 2025, ScienceSoft became a Gold Member of the Healthcare Information and Management Systems Society (HIMSS). This membership gives our specialists additional access to industry frameworks, education, and peer knowledge as they continue strengthening their healthcare IT expertise. What impacts healthcare IT the most today, and how does it change the way ScienceSoft operates? I think the change with the broadest impact right now is the rapid development and adoption of AI. Providers are already introducing it into clinical and administrative work, while major technology companies are reshaping their products and roadmaps around it. There is much more interest in what AI can realistically improve, but ScienceSoft is a pioneering AI transformation and software development partner for healthcare organizations. We are proud to hear more directly from Hadeel Abu Baker, Senior Healthcare IT & AI Consultant, as the company was recently awarded the title of Leading Healthcare Software Provider 2026 in this year’s Global Excellence Awards. Healthcare Streamlined with ScienceSoft also more caution around reliability, data governance, compliance, and the effort needed to introduce it into day-to-day work. This is an area where our healthcare and engineering experience can make a practical difference. That is why AI transformation has become a major part of our offering. We want to help healthcare organizations rethink and improve administrative and clinical operations with AI. You use the term “transformation” rather than “implementation” or “adoption”. What is the difference? If AI remains a separate tool beside the process, it may make one task easier but leave the rest of the work unchanged. We call it transformation when AI becomes part of the process itself, changes how work moves from one step to another, and produces measurable results throughout the process or the entire organization. In healthcare, these results are often operational at first: shorter cycle times, less manual work, higher staff capacity, fewer delays, or better access to services. But they directly affect how much the organization spends, how much work it can handle, and, in some cases, how much revenue it can generate. What does AI transformation look like in practice for a healthcare organization? Let’s look at the revenue cycle. We may start with prior authorization, where AI assembles submission packages, checks payer requirements, and flags missing information for staff review. If the KPIs show tangible improvements, it can be extended to connected workflows like coding, claim preparation, quality checks, and denial management. At this point, the organization begins to redesign the revenue cycle end-to-end: deciding which tasks AI can handle directly, where human approval remains necessary, and how roles and handoffs should change. Broader use also requires clear rules for validation and monitoring, with tighter controls for higher-risk tasks. This is where we start talking about transformation. Contact: Alexa Tsviatkova Company: ScienceSoft Website: www.scnsoft.com/healthcare T Jul26009
12 GHP Q3 2026 n the rapidly evolving landscape of health and biotechnology, Astrobiome® stands out as a trailblazer, earning the prestigious GHP Global Excellence Award as the Most Innovative Microbiome Therapeutics Company 2026. By fusing advanced space biotechnology with ancient Japanese fermentation mastery, Astrobiome is redefining microbiome science through its groundbreaking Super-Postbiotics™, naturally produced fullspectrum metabolite complexes designed to support human health and longevity, with applications for regenerative agriculture both on Earth and beyond. Founded in 2023 in Luxembourg, Astrobiome Space, SARL (with original HQ in Houston, TX, USA), the company leverages extreme environments to create dynamic metabolic therapeutic solutions. Its mission is clear: upgrade human health and food systems to survive long-duration space missions, while delivering extraordinary benefits to humanity on Earth facing climate uncertainty and health decline. Drawing on over 30 years of studies in extreme conditions, including collaborations with institutions like the National Aeronautics and Space Administration(NASA), the Luxembourg Space Agency (LSA), and the European Space Agency (ESA), Astrobiome Space uses proprietary methods to expose the selected bacterial strains to the unique stresses of microgravity. Utilizing the access to the International Space Station (ISS) laboratory, the company optimizes metabolite production in microgravity and has discovered new bioactive compounds that can only be achieved from these types of strains through stimulation in the space environment. This results in space-adapted Champion Strains™ that generate more than 600 detectable bioactive metabolites in synergistic harmony. Unlike traditional probiotics, these stable postbiotics – which contain no live bacteria – deliver bioactive compounds via skin or direct digestive absorption. They support deep microbiome balance, intestinal barrier integrity, immune modulation, nutrient absorption, and systemic health without added sugar. Key benefits, testified by users and backed by the company’s clinical tests, include enhanced gut-brain axis function (improved mood, focus, and reduced anxiety/ADHD symptoms), deeper sleep and recovery, reduced inflammation and joint pain, better blood sugar regulation, liver support, energy restoration, and overall cellular resilience — even against stressors like radiation. Testimonials from astronauts, athletes, NASA engineers, post-partum moms, and everyday users highlight transformative effects on immunity, digestion, vitality, and longevity. I Awarded with the title of Most Innovative Microbiome Therapeutics Company 2026 in this year’s Global Excellence Awards, Astrobiome Space is an extraordinary, award-winning business making a positive impact on the integral health and biotechnology sphere. We take a closer look below. Astrobiome®’s approach is rooted in precision fermentation in partnering Tokyo labs, including Tokyo University and Kyoto University, inspired by Blue Zones centenarians and combined with space-enhanced evolution. This yields highquality, consistent, superior postbiotic formulations that are shelf-stable and suitable for sensitive systems. The company’s work extends beyond human therapeutics: its microbiomebased biostimulants support regenerative agriculture, soil remediation, and plant resilience – with successful experiments like strawberry growth in space via Luxembourg Space Agency (LSA) LuxImpulse collaborations. Previous accolades, including Top Agri Biotech Solutions Provider (2024), Space Impact Hall of Fame recognition, and multiple LSA partnerships, underscore Astrobiome’s leadership at the intersection of microbiome science, epigenetics, postbiotics, and astrobiology. As microbiome research reveals the gut’s central role in immunity, metabolism, mental well-being, and aging, Astrobiome Space positions postbiotics as the next frontier, moving beyond symptom management toward proactive, cellular-level regeneration and healthy longevity. Its innovations promise to transform human wellness and advance sustainable farming practices critical for Earth and future space missions. To make this complex technology accessible for everyday lives, the company is expanding the Astrobiome-INSIDE™ concept, inviting food and beverage companies to collaborate on the first postbiotic-integrated snacks, super-foods, and premium cosmetics. Vera Mulyani, CEO and Founder, emphasizes transitioning from chemical-dependent systems to natural microbiome solutions to address climate and health challenges. With its 2026 GHP recognition, Astrobiome exemplifies how bold scientific vision, rooted in space research and traditional wisdom, can deliver innovative therapeutics that nourish life at every level. For more on Astrobiome®’s Super-Postbiotics™ and mission, visit the website today. The real meaning of the buzzword “longevity” is experienced here with Astrobiome® — resilient, regenerative, and ready for humanity’s greatest challenges. Contact: Vera Mulyani Company: Astrobiome Space Website: https://astrobiome.space/ Astrobiome Space: Pioneering the Next Era of Microbiome Therapeutics
13 GHP Q3 2026 KH Medical Aesthetics & Skincare is led by Katie Hampson, a specialist in skin rejuvenation and problematic skin. After spending 12 years looking after patients in the NHS, Katie took a leap into aesthetics and skin to follow a passion she had held for a number of years. With a younger daughter at home, Katie was determined to provide her with a strong example of how hard work and determination can enable anyone to pursue their dreams. Katie established KH Medical Aesthetics & Skincare with a focus on taking a clinical, evidence-led approach to aesthetics and skincare. Over the years, she has established the clinic as a trusted partner to clients across Greater Manchester, bringing a strong foundation of clinical knowledge, assessment, and patient care to an industry often dominated by fleeting trends. Every treatment is tailored to restore confidence, enhance natural beauty, and support longterm skin health. “My mission is to provide safe, evidence-led, and personalised aesthetic and skincare treatments that enhance natural results and improve the long-term healthy and quality of our clients’ skin,” Katie shared. “Every client is different, and my role is to understand their individual needs, educate them, and create a considered treatment plan based on their skin, anatomy, goals, and the best available evidence.” In a saturated market, this is precisely what propels KH Medical Aesthetics & Skincare to stand at the forefront of the industry. Every client receives comprehensive consultations and objective skin analysis using advanced technology to understand what is happening beneath the surface of the skin. This enables Katie to create genuinely personalised treatment plans based on what their skin needs, rather than simply recommending what is currently popular. This is paired with a long-term approach to skin health. Rather than focusing on quick fixes and selling individual treatments, KH Medical Aesthetics & Skincare offers a comprehensive suite of regenerative skin treatments that bring together advanced treatments including Profhilo, Profhilo Structura, Polynucleotides, amino acid-based treatments, and microneedling, alongside carefully considered combination treatment plans. With KH Medical Aesthetics & Skincare’s regenerative approach, clients benefit from improvements in skin quality, hydration, texture, firmness, elasticity, and overall radiance, achieved through treatment plans designed around their individual concerns and long-term goals. For some clients, this may involve one regenerative treatment, while others benefit from combining different modalities to address multiple aspects of ageing and skin health. Located in the heart of Chadderton, Manchester, KH Medical Aesthetics & Skincare is a leading clinic dedicated to helping its clients look and feel their absolute best. The clinic has earned acclaim for its regenerative approach to skin health, building its practice around real evidence instead of fleeting trends. We heard more from Founder Katie Hampson below, as KH Medical Aesthetics & Skincare is named Greater Manchester’s Best Skin Rejuvenation Clinic 2026 in the Global Excellence Awards 2026. Leading the Regenerative Revolution in Aesthetics and Skincare “I believe the future of aesthetics is not about changing a person’s appearance, but about supporting the skin’s natural ability to regenerate, improve its quality, and age well,” Katie explained. “What makes my approach different is the emphasis on combination treatments and long-term planning. I don’t believe one treatment can address every aspect of ageing. By understanding the skin and underlying changes, we can strategically combine treatments to achieve more comprehensive and natural looking results.” Embracing the industry-wide shift towards regenerative skincare has brought significant advantages to KH Medical Aesthetics & Skincare. This evolution has allowed Katie to differentiate her practice from the more trend-led providers whilst positioning the clinic around education, clinical knowledge, and personalised care. It has played a key role in strengthening client trust, as Katie can now not only explain what is recommended, but why. Looking to the future, Katie intends to continue challenging the way aesthetic clinics operate by creating a unique model that combines clinical expertise, advanced technology, personalised treatment planning, and practitioner education. With this, we will move KH Medical Aesthetics & Skincare further away from a treatmentled model and towards a skin health and long-term aging model, delivering exceptional treatment programmes centred on skin health, regeneration, and long-term results. “I want to demonstrate that aesthetics can be commercially successful while remaining clinically responsive, evidence-led, and genuinely client-focused,” Katie concluded. “Ultimately, my ambition is to become a leading name in skin health, advanced aesthetics, and practitioner education within Greater Manchester and beyond, while creating a business with a reputation for clinical excellence, innovation, education, and natural results.” Contact: Katie Hampson Company: KH Medical Aesthetics & Skincare Web Address: www.khaestheticsandskincare.co.uk
14 For almost five decades, Bass Brushes has designed luxury-grade hairbrushes, spa and body tools, men’s grooming tools, cosmetic brushes, and personal care accessories specialising in premium natural materials. Today, the products are surprisingly affordable and recommended by professional hairstylists worldwide. We heard more from Joel Weinstein in the wake of the organization’s recent win of Best Premium Brush Brand 2026 - USA in the Global Excellence Awards 2026. For nearly 50 years, personal grooming has stood as one of the most fundamental expressions of human creativity. Every single day provides a fresh canvas to craft, refine, and transform shapes, textures, colours, and dimensions. This intentional act of styling yields an individual aesthetic - a physical emanation of something far deeper within each person. At the heart of this routine sits a tool so essential that its quality dictates the success of the outcome: the hairbrush. Bass Brushes has spent nearly five decades redefining what this humble instrument can achieve. Expertly crafted with a resolute focus on natural materials, Bass designs luxury-grade brushes for both women and men that remain surprisingly affordable while earning recommendations from professional hairstylists and barbers worldwide. From its origins in a California family garage to its position today as an internationally distributed brand, Bass Brushes proves that true artistry thrives at the intersection of heritage craftsmanship, continuous innovation, and deep educational outreach. The story of Bass Brushes is rooted in authentic professional practice. The company was founded by Ron Weinstein, a professional stylist whose journey began behind the chair in Burbank, California. Operating a small, single-chair boutique salon located near the NBC television studios, Ron developed a devoted client base that included notable daytime television personalities. However, as the financial responsibilities of raising a young family grew, Ron took on supplemental work on weekends selling hairbrushes for a local distributor. What started as a side effort rapidly ignited a much larger vision. Recognising a gap in the market for high-performing tools crafted from superior natural materials, Ron began developing a small core group of brush models. He converted his family’s small garage into a makeshift office, warehouse, and distribution hub. As demand for his designs steadily expanded, Ron made the decision to close his salon and dedicate himself entirely to brush making. “Our philosophy is rooted in the belief that the hairbrush is an intuitive extension of the hand,” said Joel Weinstein, President and Co-Owner. “It is one of the most fundamental grooming tools. The interaction between the hand, the tool, and the hair - the motion, the intention, the result, and the feeling when that intention is realized - is a constant inspiration for us.” Today, Bass Brushes operates as a second-generation family business under the leadership of Ron’s sons, Joel and Cory Weinstein. Having grown up packing orders in that very same Burbank garage, Joel and Cory have expanded the company’s distribution footprint across the United States and international markets. While the scale of the business has grown significantly, the founding spirit remains completely intact. “Having stayed sincere to our founder’s core mission, the brand is not different today in spirit,” Joel noted. “Rather, it is a more perfected and refined version of what it was always striving for, focusing on the underlying intangible truth that makes the hairbrush an essential and elevating tool of personal expression.” What allows Bass Brushes to stand out in a crowded global marketplace is its distinct background as one of the few brush manufacturers founded directly by professional stylists. This practical origin provides an irreplaceable perspective during every phase of product development. By evaluating design choices through the lens of daily salon and barbering applications, Bass creates implements that satisfy the rigorous demands of professional artists while offering everyday consumers an inherently superior product. Every element of a Bass brush represents a synthesis of classic elegance and modern ergonomics. Combining advanced manufacturing expertise with premium natural materials, including sustainably sourced wood, bamboo, and pure natural bristles, Bass delivers purposeful function across every imaginable hair type, texture, cut, and style. Over the decades, Bass has driven the industry forward through a commitment to structural innovation, securing multiple patents for original brush designs. “Innovation for us is not about novelty for its own sake,” explained Joel. “It is about continually finding ways to refine the tool, improve its function, and enrich the experience of using it.” A Clean Sweep
GHP Q3 2026 A prime showcase of this design approach is the multi-patented FUSION Brush. The FUSION Brush embodies the brand’s drive to merge structural innovation with seamless handling, providing hair artists and everyday users alike with optimal control and effortless styling performance. Bass Brushes views its responsibility as extending far beyond manufacturing. A key cornerstone of the company’s mission is empowering stylists, barbers, and everyday shoppers through unbiased, practical knowledge. Through the Bass Education & Insights Journal, the brand has built a dedicated, continually expanding digital publishing platform. This resource offers in-depth analysis on brushing mechanics, hair material science, structural brush engineering, and specific styling techniques. By teaching people why specific brush builds perform the way they do, Bass ensures that users can select the precise implement needed to realise their desired look without damaging their hair. “Education is equally important to us,” Joel emphasized. “We believe a great brush company should not only make exceptional tools but also help people better understand how and why they work.” As Bass Brushes continues its journey toward half a century in business, its roadmap for the future remains focused on sustainable growth, craftsmanship, and enhanced accessibility. Over the next five years, the company plans to build upon its patented design portfolio, broaden the reach of its educational initiatives, and ensure elevated grooming tools remain available to consumers everywhere. By honoring Ron Weinstein’s original garage-founded endeavor while continually advancing modern manufacturing standards, Joel and Cory Weinstein maintain a bridge between classic heritage and contemporary beauty standards. Bass Brushes remains proof that when a tool is crafted with genuine purpose, personal grooming transcends routine to become something truly sublime. Contact: Joel Weinstein Company: Bass Brushes Web Address: www.bassbrushes.com
16 GHP Q3 2026 In today’s fast-moving medical device sector, every delivery carries real weight for patient care. A delay or compliance issue can put outcomes at risk, so whether a shipment needs to reach Belgium, the Netherlands, Germany, France, Spain, Italy or beyond, Medical Logistics promises to deliver compliantly on time and fully documented. We took a closer look as the company earns praise at the Global Excellence Awards 2026. “You bring the product; we handle regulatory compliance, logistics and customer service in every market.” Based in Mechelen and active across Europe, Medical Logistics is the dedicated Benelux operations hub for international medical device manufacturers and distributors, setting the benchmark for operational excellence, innovation and outstanding customer service across the industry. From its ISO 13485:2016- and GMP-certified, CO₂-neutral warehouse in Mechelen, the company reaches the entire Benelux region directly, backed by an established partner network across Western, Eastern and Southern Europe for fast market entry. At a glance • Established in 2005 • Two decades supporting healthcare professionals • 47,800+ orders shipped • 1.69 million+ scans executed • Delivery across Europe within 24–72 hours Founder Filip Waulet spent years working alongside healthcare organisations and medical technology companies before identifying the gap he would later build Medical Logistics to fill: traditional logistics providers focused on transport alone, while medical device companies needed a partner combining operational excellence with genuinely client-centric service. That insight shaped the company from day one, and it has since grown into a key operations hub for medical distributors across the Benelux region. Rather than acting as just another logistics partner, Medical Logistics becomes an extension of its clients’ businesses, learning their products, customers and operational challenges to build solutions tailored to their needs. Clients receive a comprehensive suite of logistics and customer services—warehousing, compliance, customer service and last-mile delivery—all under one roof as a single integrated service model. Working with Medical Logistics means full traceability and monitoring of medical devices, diagnostics, pharmaceuticals and tissue materials. The team manages every touchpoint on the client’s behalf, from order intake through to complete customer service, delivered in a personalised manner that reflects the client’s own brand. Regulatory support is central to the offering, with expert guidance through FAMHP access procedures for distributors entering the Belgian market. On the digital side, the company connects clients’ online product catalogues directly to ordering and invoicing— including Peppol e-invoicing—and provides real-time visibility into orders, shipments, temperatures and compliance information through its own in-house platform. Supporting healthcare professionals since 2005, Medical Logistics has now shipped more than 47,800 orders and processed over 1.69 million scans. These figures reflect two decades of proof that medical device logistics involves far more than moving products from A to B—it requires trust, dedication and an unwavering commitment to customer excellence. It is for this reason that Global Health & Pharma Magazine is proud to recognise Medical Logistics as Europe’s Best Medical Device Logistics Company 2026. Congratulations to the whole team—we look forward to another year of exceptional medical logistics delivery. Contact: Filip Waulet Company: Medical Logistics Web address: www.medicallogistics.eu Medical Logistics: “Your Customer, Our Care” ISO 13485:2016 GMP certified CO₂-neutral Full traceability and monitoring for medical devices and diagnostics — every shipment handled with care, precision, and compliance. Medical devices Validated handling, end-to-end chain of custody Diagnostics Temperature-monitored, time-critical delivery 24–72h delivery across Europe, from Mechelen SCAN TO VISIT www.medicallogistics.eu your customer, our care Mechelen · Benelux MED LOG your customer, our care LIVE TRACKED MEDICAL LOGISTICS · MECHELEN Smart medical logistics, handled with care.
ghpnews.digitalRkJQdWJsaXNoZXIy MTUyMDQwMA==